A New Alzheimer’s Drug Offers More Questions Than Answers
>
The approval of Aduhelm to treat Alzheimer’s disease has raised hope among older adults, but many doctors wonder if it is warranted. About Ukraine RussiaMore Posts
Are you witnessing a dramatic incident? You see something and want to share it worldwide. Write news or information here, upload pictures or videos and earn money a month. Register and get started immediately. Take part!
News Post or Image uploaden – press here
>
The approval of Aduhelm to treat Alzheimer’s disease has raised hope among older adults, but many doctors wonder if it is warranted. About Ukraine RussiaMore Posts
The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules. About Ukraine RussiaMore Posts
The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms. About Ukraine RussiaMore Posts
The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients. About Ukraine RussiaMore Posts
If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works. About Ukraine RussiaMore Posts
Aducanumab is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say there’s not enough evidence it can address cognitive symptoms. About Ukraine RussiaMore […]
If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works. About Ukraine RussiaMore Posts